Forstavir-3 is a fixed-dose combination tablet that contains 600 mg of Efavirenz, 200 mg of Emtricitabine, and 245 mg of Tenofovir Disoproxil Fumarate. It is an antiretroviral medication used to treat human immunodeficiency virus (HIV) infection in adults and children.
Composition:
- Efavirenz: 600 mg
- Emtricitabine: 200 mg
- Tenofovir Disoproxil Fumarate: 245 mg
- Tablet core: croscarmellose sodium, lactose monohydrate, magnesium stearate
- Film coating: hypromellose, polyethylene glycol, titanium dioxide
Mechanism of Action:
Forstavir-3 works by inhibiting the activity of HIV reverse transcriptase (Emtricitabine and Tenofovir), an enzyme necessary for the virus to replicate. Efavirenz also works by binding to the HIV-1 capsid protein, which helps to prevent the virus from replicating.
Uses:
Forstavir-3 is used to treat HIV infection in adults and children. It is recommended for patients who have not previously received antiretroviral therapy or who have failed other antiretroviral regimens.
Dosage:
The recommended dosage of Forstavir-3 is one tablet once daily, taken at bedtime.
Side Effects:
Common side effects of Forstavir-3 include:
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
- Insomnia
- Dizziness
- Increased liver enzymes
- Increased blood lipids
- Kidney damage (in patients with pre-existing kidney disease)
Recommendation:
Forstavir-3 should be used under the guidance of a healthcare professional. Patients should be monitored regularly for liver function tests, lipid profiles, and glucose levels.
Important Note:
- Forstavir-3 is not recommended for use in patients with severe liver disease (Child-Pugh C).
- Patients with pre-existing kidney disease should be monitored closely for signs of kidney damage or toxicity.
- Patients taking other medications, including antiretroviral agents, may be at risk for interactions with Forstavir-3.
- The safety and efficacy of Forstavir-3 in pregnant or lactating women have not been established.
- Forstavir-3 is not recommended for use in children under 6 months of age.
- Patients should be counseled on the importance of taking concomitant therapy as prescribed by their healthcare provider.
- Patients should be monitored for neuropsychiatric symptoms, such as depression, anxiety, and sleep disorders.
It is essential to follow the recommended dosage and monitoring guidelines to ensure safe and effective treatment.
Reviews
There are no reviews yet.